Literature DB >> 21766498

Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis.

V Pecic1, D Stankovic-Djordjevic, M Nestorovic, M Radojkovic, H Marjanovic, B Ilic, M Milojkovic.   

Abstract

PURPOSE: The aim of this study was to compare patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) infection with patients with liver cirrhosis associated with HCV virus infection.
METHODS: Forty-five patients were prospectively analyzed, all with HCV infection. Patients were divided into 2 groups. The first group consisted of 21 patients with histologically proven HCC and the second one consisted of 24 patients with liver cirrhosis without HCC. PCR was carried out in order to diagnose active HCV infection and HCV genotyping.
RESULTS: There was no statistically significant difference in the structure of the compared groups of patients in relation to sex and age. In 76.19% of the patients with HCC cirrhosis preceded HCC, while 23.81% of the patients had chronic hepatitis. The prevalence of genotypes in the HCC group was 1a in 4.76%, 1b in 80.95% and 2a in 14.29%. In the group with liver cirrhosis 1a was detected in 20.83%, 1b in 45.83%, 2a in 12.50%, 2b in 4.17% and 3a in 16.67% of the patients. The prevalence of genotype 1b was significantly higher among HCV RNA positive patients with HCC compared to the group with liver cirrhosis and HCV RNA positive patients (x(2)=4.48; p=0.034). In the group where cirrhosis preceded HCC, genotype 1b was found in 75% of the cases, genotype 2a in 18.75%, and genotype 1a in 6.25%. Genotype 1b was detected in 100% of patients with chronic hepatitis and HCC.
CONCLUSION: The role of HCV infection in the development of HCC has not been fully clarified. Most authors evaluate the role of individual genotypes in the pathogenesis of HCC. This study has shown that the dominant genotype found in patients with HCC is 1b.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766498

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

1.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

2.  Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study.

Authors:  Chia-Hung Kao; Li-Min Sun; Ji-An Liang; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

3.  Association between Sedative-hypnotics and Subsequent Cancer in Patients with and without Insomnia: A 14-year Follow-up Study in Taiwan.

Authors:  Hui-Fen Fang; Tzu-Yin Lee; King Cheung Hui; Howard Chi Ho Yim; Mei-Ju Chi; Min-Huey Chung
Journal:  J Cancer       Date:  2019-05-21       Impact factor: 4.207

4.  Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients.

Authors:  Mihajlo Jakovljevic; Zeljko Mijailovic; Biljana Popovska Jovicic; Predrag Canovic; Olgica Gajovic; Mirjana Jovanovic; Dejan Petrovic; Olivera Milovanovic; Natasa Djordjevic
Journal:  Hepat Mon       Date:  2013-06-19       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.